Overview

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see whether CDX-011 is effective in treating patients who have advanced breast cancer that makes a protein called glycoprotein NMB (GPNMB), and who have already received (or were not candidates for) all available approved therapies for their breast cancer. This study will also further characterize the safety of CDX-011 treatment in this patient population.
Phase:
Phase 2
Details
Lead Sponsor:
Celldex Therapeutics
Treatments:
Antibodies, Monoclonal
Glembatumumab vedotin